China
Africa
Explore chapters and articles related to this topic
Antitubulin Agents
Published in David E. Thurston, Ilona Pysz, Chemistry and Pharmacology of Anticancer Drugs, 2021
In 2007 the FDA-approved ixabepilone as a monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. The FDA also granted approval for use in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline, and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. At the time of writing the EMA has not approved a marketing authorization for ixabepilone (refused in 2008), and ixabepilone has not been approved by NICE for use in the UK.
Drug profiles: generic names A-Z
Published in Jerome Z. Litt, Neil H. Shear, Litt's Drug Eruption & Reaction Manual, 2017
Clinically important, potentially hazardous interactions with: albendazole, aminoglutethimide, amprenavir, aprepitant, aspirin, bexarotene, boceprevir, carbamazepine, caspofungin, cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil, cyclophosphamide, dasatinib, delavirdine, diuretics, ephedrine, imatinib, itraconazole, ixabepilone, lapatinib, lenalidomide, live vaccines, lopinavir, methotrexate, midazolam, phenobarbital, phenytoin, praziquantel, primidone, rifampin, rilpivirine, romidepsin, simeprevir, sorafenib, sunitinib, telaprevir, temsirolimus, ticagrelor, vandetanib, warfarin
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan
Published in Expert Opinion on Biological Therapy, 2021
Julia E. McGuinness, Kevin Kalinsky
Cytotoxic chemotherapy remains the standard of care in the first-line metastatic setting given the lack of efficacy of endocrine or HER2-directed therapies. First-line chemotherapeutic agents include taxanes and platinums, with particular consideration for platinums in patients with mTNBC and germline mutations in BRCA1/2 given superior response rates with carboplatin compared to docetaxel in this population [8,9]. Among the approximately 40% of patients whose tumors express PD-L1, the preferred first-line regimen is the combination of the immune checkpoint inhibitor atezolizumab with nab-paclitaxel, based upon the results of the IMpassion130 trial demonstrating superior progression-free survival (PFS) and numerically higher OS with chemoimmunotherapy versus chemotherapy alone [10]. In relapsed or refractory disease, single-agent chemotherapies including anti-metabolites (capecitabine, gemcitabine), and anti-microtubule agents (eribulin, vinorelbine, ixabepilone) remain options, but overall response rates (ORR) are generally less than 20%, with median PFS approximately two to 4 months [11–13]. There is therefore a clear unmet need to develop novel therapeutic agents in this patient population.
Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma
Published in Expert Review of Anticancer Therapy, 2018
Pol Specenier, Jan B Vermorken
In a randomized phase II trial, 101 patients with incurable HNSCC progressing after platinum-based therapy were randomized between cabazitaxel every 3 weeks at a starting dose of 20 mg/m2, which could be increased to 25 mg/m2 if toxicity permitted for subsequent cycles, or methotrexate, 40 mg/m2/week. Cabazitaxel was more toxic and failed to improve PFS (primary endpoint) [61]. Ixabepilone is a tubulin-polymerizing agent. The ECOG randomly assigned 85 R/M HNSCC patients who had received ≤ 2 prior regimens for recurrent/metastatic disease, to receive ixabepilone 6 mg/m2/day × 5 days every 21 days or 20 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Based on the poor efficacy and high incidence of neuropathy, further development of ixabepilone in previously treated HNSCC is not warranted [62].
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds
Published in Expert Opinion on Investigational Drugs, 2019
Marco Tagliamento, Carlo Genova, Giovanni Rossi, Simona Coco, Erika Rijavec, Maria Giovanna Dal Bello, Simona Boccardo, Francesco Grossi, Angela Alama
Two phase I trials investigated the association of ixabepilone and platinum compounds. The first study was performed in 24 pretreated patients receiving ixabepilone and cisplatin. Among those treated with the cisplatin dose of 60 mg/m2, 8 reported PR and 10 had stable disease (SD). Conversely, among the 5 patients who received cisplatin at 80 mg/m2, 2 reported SD. Drug-related serious AEs were registered in 5 out of 29 patients (NCT00832117). The second study, carried out in 12 chemotherapy-naïve patients treated with ixabepilone and carboplatin, reported 3 PR and 4 SD (with carboplatin administered at 5 or 6 mg/min/mL). There were 3 treatment-related AEs leading to discontinuation (NCT00683904).